AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17352269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoplatin/5-FU
Number of subjects: 12
Study 17352269 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5-FU
Number of subjects: 12
Study 15200199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4mg)
Number of subjects: 70
Study 15200199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11473220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported STD status
Number of subjects: 522
Study 11473220 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate reporting of positive STD status
Number of subjects: 522
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 10 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 4067
Study 9916605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4067
Study 8066849 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up home visits by a district nurse and general practitioner
Number of subjects: 344
Study 8066849 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge procedures
Number of subjects: 344
Study 8066849 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up home visits
Number of subjects: 344
Study 3195836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (20 mg 3 times a day)
Number of subjects: 15
Study 3195836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29472265 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamin B12 supplementation (at least two recommended dietary allowances daily for at least 6 months)
Number of subjects: 0
Study 31416769 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg three times daily)
Number of subjects: 147
Study 31416769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 31416769 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 147
Study 28646893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib and vemurafenib
Number of subjects: 493
Study 28646893 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib
Number of subjects: 493
Study 25123377 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 6
Study 23623342 — intervention group
Group type: EXPERIMENTAL
Intervention: Carto‐Sound
Number of subjects: 60
Study 23623342 — intervention group
Group type: COMPARATOR
Intervention: Electro-anatomic mapping (EAM)
Number of subjects: 60
Study 22137134 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic location of primary melanoma (head/neck, trunk, upper extremity, lower extremity)
Number of subjects: 2500
Study 22137134 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analysis of anatomic location
Number of subjects: 2500
Study 19224292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Roux‐en‐Y gastrojejunostomy reconstruction with jejunostomy feeding tube
Number of subjects: 247
Study 19224292 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastric bypass (control group)
Number of subjects: 247
Study 19224292 — intervention group
Group type: COMPARATOR
Intervention: Comparison of modified group vs control group
Number of subjects: 247
Study 16686550 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 9
Study 16686550 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 9
Study 12874531 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (50 mg of powder of red pepper with 0.25% of capsaicin)
Number of subjects: 84
Study 12874531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty capsules)
Number of subjects: 84
Study 10919900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% four times daily
Number of subjects: 117
Study 10919900 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears four times daily
Number of subjects: 117
Study 10919900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5%
Number of subjects: 117
Study 10919900 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 117
Study 9004191 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release experimental formulations (80 mg)
Number of subjects: 0
Study 9004191 — intervention group
Group type: COMPARATOR
Intervention: Inderal LA (80 mg)
Number of subjects: 0
Study 9004191 — intervention group
Group type: COMPARATOR
Intervention: Inderal immediate-release dosage form (2 x 40 mg)
Number of subjects: 0
Study 1359318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether at 700 mg total dose over 5 days
Number of subjects: 46
Study 1359318 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine 1250 mg in divided doses
Number of subjects: 46
Study 4050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-course radiotherapy (6,000 cGy in 30 fractions of 200 cGy each, over 6 weeks)
Number of subjects: 148
Study 4050737 — intervention group
Group type: COMPARATOR
Intervention: Split-course radiotherapy (2,750 cGy in 10 fractions of 275 cGy each, over 2 weeks; a rest period of 3 weeks; 2,750 cGy in 2 weeks)
Number of subjects: 148
Study 31678689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on multivariate analysis with Cox proportional hazards regression.
Number of subjects: 19796
Study 31678689 — intervention group
Group type: COMPARATOR
Intervention: Training cohort (n = 13,860) and validation cohort (n = 5,936) used for analysis.
Number of subjects: 19796
Study 28962869 — intervention group
Group type: EXPERIMENTAL
Intervention: High provider anxiety
Number of subjects: 148
Study 28962869 — intervention group
Group type: COMPARATOR
Intervention: Low provider anxiety
Number of subjects: 148
Study 27182015 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking prevention program for preschool children (6 weeks duration)
Number of subjects: 123
Study 25148184 — intervention group
Group type: EXPERIMENTAL
Intervention: MR enterography measurement
Number of subjects: 31
Study 22945714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH) 2 placed in the dried pulp chamber
Number of subjects: 99
Study 22945714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH) 2 placed in dried root canals
Number of subjects: 99
Study 22945714 — intervention group
Group type: COMPARATOR
Intervention: Control group (canals remained wet without medication)
Number of subjects: 99
Study 20864904 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 24
Study 20864904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19012119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 47
Study 19012119 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study 19012119 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 47
Study 16816529 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 16816529 — intervention group
Group type: COMPARATOR
Intervention: Conventional yoghurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Number of subjects: 33
Study 14531869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyral in ethanol (6% to 6 p.p.m)
Number of subjects: 25
Study 14531869 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control of ethanol
Number of subjects: 25
Study 14531869 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 subjects)
Number of subjects: 25
Study 10448445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 10448445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7479231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 15
Study 7479231 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 15
Study 2129319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg PM
Number of subjects: 196
Study 2129319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg bid
Number of subjects: 196
Study 2129319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg AM
Number of subjects: 196
Study 2129319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (all regimens)
Number of subjects: 196
Study 2129319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDX)
Number of subjects: 15
Study 364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylchlordiazepoxide (DMCDX)
Number of subjects: 15
Study 364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Demoxepam (DMX)
Number of subjects: 15
Study 364999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30982356 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone treatment in Study MCI186-19
Number of subjects: 0
Study 30982356 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Study MCI186-16
Number of subjects: 0
Study 30982356 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Study MCI186-19
Number of subjects: 0
Study 29871204 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline nasal irrigation at 40 degrees
Number of subjects: 120
Study 29871204 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation at 25 degrees (control)
Number of subjects: 120
Study 25521103 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-501-B
Number of subjects: 103
Study 25521103 — intervention group
Group type: COMPARATOR
Intervention: Restylane Perlane
Number of subjects: 103
Study 23344712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day (fasted) on Days 2-8 and 1,600 mg (with food) on Day 9
Number of subjects: 96
Study 23344712 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 96
Study 23344712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 96
Study 20840529 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 20 mg hyperbaric bupivacaine and 0.2 mg morphine
Number of subjects: 162
Study 20840529 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with propofol, fentanyl and rocuronium
Number of subjects: 162
Study 18030490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposures (IHE) for 10 days
Number of subjects: 8
Study 18030490 — intervention group
Group type: COMPARATOR
Intervention: Placebo control for 10 days
Number of subjects: 8
Study 16423331 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg memantine
Number of subjects: 32
Study 16423331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12603365 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 0
Study 12603365 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 0
Study 11445103 — intervention group
Group type: EXPERIMENTAL
Intervention: Human IgG 1200 mg/kg daily
Number of subjects: 768
Study 11445103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 9727900 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 IU/day for 3 months)
Number of subjects: 29
Study 9727900 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29
Study 8021679 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy for arm function
Number of subjects: 97
Study 8021679 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 97
Study 2690785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 26
Study 2690785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 26
Study 2690785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance low-dose paclitaxel 40 mg/m²/week for 24 weeks
Number of subjects: 542
Study 21529904 — intervention group
Group type: COMPARATOR
Intervention: Observation (no maintenance therapy)
Number of subjects: 542
Study 21529904 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance low-dose paclitaxel
Number of subjects: 542
Study 21529904 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 542
Study 6985833 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-Provera
Number of subjects: 114
Study 6985833 — intervention group
Group type: COMPARATOR
Intervention: Delalutin
Number of subjects: 114
Study 6985833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 114
Study 31279925 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 68
Study 31279925 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 68
Study 29650688 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (doxorubicin, doxorubicin + ifosfamide, epirubicin, trabectedin, ifosfamide)
Number of subjects: 348
Study 29650688 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy (for patients aged <65 years)
Number of subjects: 348
Study 26868683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)
Number of subjects: 100
Study 26868683 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD)
Number of subjects: 100
Study 26868683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 100
Study 26868683 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 100
Study 24852464 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5-fluorouracil cream applied every day for 4 weeks
Number of subjects: 32
Study 24852464 — intervention group
Group type: COMPARATOR
Intervention: 4 weekly peels of 5% 5-fluorouracil
Number of subjects: 32
Study 22573238 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher hemoglobin arm
Number of subjects: 1421
Study 22573238 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in ESA doses (>0 U)
Number of subjects: 1421
Study 22573238 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger increases in hemoglobin (>1.0 g/dL/month)
Number of subjects: 1421
Study 22573238 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing DBP
Number of subjects: 1421
Study 19092242 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 15% for 10 min
Number of subjects: 18
Study 19092242 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 of 10% for 10 min
Number of subjects: 18
Study 19092242 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA) for 20 min (control)
Number of subjects: 18
Study 17467411 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo expectation condition
Number of subjects: 56
Study 17467411 — intervention group
Group type: COMPARATOR
Intervention: Treatment control condition
Number of subjects: 56
Study 17467411 — intervention group
Group type: COMPARATOR
Intervention: No‐placebo control condition
Number of subjects: 56
Study 15178637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 4 weeks
Number of subjects: 20
Study 15178637 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study 12077469 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturiser containing urea and sodium chloride
Number of subjects: 23
Study 12077469 — intervention group
Group type: COMPARATOR
Intervention: Moisturiser containing urea alone
Number of subjects: 23
Study 10097818 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant thrombopoietin therapy; details on dosage and duration not available.
Number of subjects: 0
Study 10097818 — intervention group
Group type: EXPERIMENTAL
Intervention: Short peptides with Tpo activity; details on dosage and duration not available.
Number of subjects: 0
Study 7651063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 30
Study 7651063 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 30
Study 7651063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2649192 — intervention group
Group type: EXPERIMENTAL
Intervention: Conray 325 (sodium iothalamate)
Number of subjects: 1699
Study 2649192 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 300 (iopamidol)
Number of subjects: 1699
Study 333693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lioresal (antispasticity drug)
Number of subjects: 15
Study 28512669 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser (NAF) with fractional micro-needling radiofrequency (FMR)
Number of subjects: 0
Study 28512669 — intervention group
Group type: COMPARATOR
Intervention: Non-ablative fractional laser (NAF) alone
Number of subjects: 0
Study 26431123 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical, cognitive, and mindfulness group-based training (PCMT group)
Number of subjects: 112
Study 26431123 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 112
Study 23992381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin sponge particles
Number of subjects: 60
Study 23992381 — intervention group
Group type: COMPARATOR
Intervention: nPVA
Number of subjects: 60
Study 21334243 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T
Number of subjects: 412
Study 21334243 — intervention group
Group type: COMPARATOR
Intervention: DTaP-IPV-Hep B//PRP-T
Number of subjects: 412
Study 19825891 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision reflexology
Number of subjects: 73
Study 19825891 — intervention group
Group type: COMPARATOR
Intervention: Sham reflexology
Number of subjects: 73
Study 16764198 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 38
Study 16764198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15039412 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study 15039412 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study 11295008 — intervention group
Group type: EXPERIMENTAL
Intervention: Home injections by the nurse practitioner
Number of subjects: 89
Study 11295008 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient clinic injections by medical staff
Number of subjects: 89
Study 9047153 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy (low-dose 0.05 mg/kg)
Number of subjects: 0
Study 9047153 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy (high-dose 0.15 mg/kg)
Number of subjects: 0
Study 9047153 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNFR:Fc therapy
Number of subjects: 0
Study 9047153 — intervention group
Group type: COMPARATOR
Intervention: Control patients receiving OKT3 therapy
Number of subjects: 0
Study 8451040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medium-dosed metoclopramide (MCL, 3.5 mg/kg b.w./cycle)
Number of subjects: 16
Study 8451040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3530049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine, 1.5 mg/kg, administered 2 minutes before laryngoscopy and intubation
Number of subjects: 16
Study 3530049 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 16
Study 3530049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and saline)
Number of subjects: 16
Study 31872408 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based critical appraisal
Number of subjects: 51
Study 31872408 — intervention group
Group type: COMPARATOR
Intervention: Free critical appraisal
Number of subjects: 51
Study 31872408 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 27793737 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin plus an aminoglycoside
Number of subjects: 322
Study 27793737 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 322
Study 27127998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 800/100 mcg
Number of subjects: 16
Study 27127998 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 800 mcg
Number of subjects: 16
Study 27127998 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol (VI) 100 mcg
Number of subjects: 16
Study 27127998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23289013 — intervention group
Group type: EXPERIMENTAL
Intervention: Visfatin RS4730153 AG genotype
Number of subjects: 88
Study 23289013 — intervention group
Group type: COMPARATOR
Intervention: Visfatin RS4730153 GG genotype
Number of subjects: 88
Study 21240023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (550 mg, 3 times per day for 10 days)
Number of subjects: 75
Study 21240023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times per day for 10 days)
Number of subjects: 75
Study 18308741 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin 1 mg
Number of subjects: 59
Study 18308741 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 1 mg followed by dobutamine infusion titrated to reverse the anticipated reduction in Svo2
Number of subjects: 59
Study 18308741 — intervention group
Group type: COMPARATOR
Intervention: Sole norepinephrine infusion (control)
Number of subjects: 59
Study 17080767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0